- The shares of the cancer therapy producer were buffeted by FDA approval and dilution.
- Their Cesium-131 based brachytherapy solutions show a lot of promise, not only in combating prostate cancer where they get most of their revenues.
- The company has a chance to scale up with the FDA approval, but they will have to speed up to warrant the current share price.
IsoRay Has Exciting Prospects
July 15th, 2018 · No Comments